Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo.
NCT ID: NCT07174648
Last Updated: 2025-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
300 participants
OBSERVATIONAL
2026-01-02
2029-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DiagRaMIE Mpox Virus-RDC for the Diagnostic of Monkeypox
NCT06840197
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
NCT04235361
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
NCT01589289
Feasibility and Usability of COVID-19 Antigen RDTs in Uganda
NCT05630300
Surveillance of AMR in DRC
NCT06821282
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A novel lateral-flow immunochromatographic duplex rapid diagnostic test (RDT) has been developed for plague, which detects both F1 and LcrV proteins, and appears superior to the current RDT detecting only F1 antigens. This index RDT (called Duplex F1V) has shown promise in detecting Yersinia pestis in various sample types, including blood, bubo aspirates, and saliva in human patients.
Cross-sectional diagnostic accuracy study in clinical suspects of plague, comparing the results of Duplex F1V RDT (index assay), with PCR (polymerase chain reaction) positivity (as reference assay) on different biological fluids and assessment of clinical outcome at the end of treatment (at day 10-14).
Nested test-negative case-control study to identify risk factors and clinical predictors in PCR-confirmed plague cases, compared to PCR-negative suspects.
The study will take place in the Ituri province of DRC, the world's largest plague focus. Participants will be recruited in health centers and reference hospitals in the health areas of Rethy, Logo and Aru where the teams of the "Centre de Recherche en Maladies Tropicales" (CRMT) of Ituri are active. Individuals ≥5 years of age presenting at the sites with clinical suspicion of plague -as per national clinical case definitions- will be enrolled after informed consent and followed-up until treatment completion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Cross-sectional Nested test-negative case-control study
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to provide voluntary consent (or voluntary assent and parental consent in case of minors.
Exclusion Criteria
* Children \<5 years of age
* Participants on antibiotic treatment ≥48h prior to recruitment
5 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ANRS | Maladies infectieuses émergentes
UNKNOWN
Institut Pasteur
INDUSTRY
Université Paris-Saclay
OTHER
Centre de Recherche en Maladies Tropicales de L'Ituri (CRMT)
UNKNOWN
Institut National pour la Recherche Biomedicale (INRB)
UNKNOWN
Institute of Tropical Medicine, Belgium
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RAPIDIT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.